SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
Status:
Withdrawn
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if adding SOM230 LAR to bortezomib and
dexamethasone is better than bortezomib and dexamethasone alone and if it should be
investigated further.